gefitinib has been researched along with pf-06463922 in 2 studies
| Studies (gefitinib) | Trials (gefitinib) | Recent Studies (post-2010) (gefitinib) | Studies (pf-06463922) | Trials (pf-06463922) | Recent Studies (post-2010) (pf-06463922) |
|---|---|---|---|---|---|
| 5,231 | 566 | 2,919 | 229 | 27 | 224 |
| Protein | Taxonomy | gefitinib (IC50) | pf-06463922 (IC50) |
|---|---|---|---|
| Sodium-dependent phosphate transport protein 2B | Homo sapiens (human) | 0.0002 | |
| HLA class II histocompatibility antigen gamma chain | Homo sapiens (human) | 0.0002 | |
| High affinity nerve growth factor receptor | Homo sapiens (human) | 0.024 | |
| Tyrosine-protein kinase Fes/Fps | Homo sapiens (human) | 0.006 | |
| Proto-oncogene tyrosine-protein kinase ROS | Homo sapiens (human) | 0.0003 | |
| Tyrosine-protein kinase Fer | Homo sapiens (human) | 0.0033 | |
| Leukocyte tyrosine kinase receptor | Homo sapiens (human) | 0.0027 | |
| Tyrosine-protein kinase FRK | Homo sapiens (human) | 0.053 | |
| Focal adhesion kinase 1 | Homo sapiens (human) | 0.017 | |
| Activated CDC42 kinase 1 | Homo sapiens (human) | 0.017 | |
| Protein-tyrosine kinase 2-beta | Homo sapiens (human) | 0.014 | |
| NT-3 growth factor receptor | Homo sapiens (human) | 0.046 | |
| Echinoderm microtubule-associated protein-like 4 | Homo sapiens (human) | 0.0186 | |
| ALK tyrosine kinase receptor | Homo sapiens (human) | 0.0177 |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 2 (100.00) | 2.80 |
| Authors | Studies |
|---|---|
| Ding, K; Lu, X; Smaill, JB | 1 |
| Eisenstein, M | 1 |
1 review(s) available for gefitinib and pf-06463922
| Article | Year |
|---|---|
Medicinal Chemistry Strategies for the Development of Kinase Inhibitors Targeting Point Mutations.
Topics: Chemistry, Pharmaceutical; Humans; Point Mutation; Protein Kinase Inhibitors | 2020 |
1 other study(ies) available for gefitinib and pf-06463922
| Article | Year |
|---|---|
New lung-cancer drugs extend survival times.
Topics: Acrylamides; Afatinib; Aminopyridines; Anaplastic Lymphoma Kinase; Aniline Compounds; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; B7-H1 Antigen; Carbazoles; Carcinoma, Non-Small-Cell Lung; Crizotinib; ErbB Receptors; Gefitinib; Hope; Humans; Lactams; Lung; Lung Neoplasms; Piperidines; Programmed Cell Death 1 Receptor; Pyrazoles; Quinazolinones; Survival Analysis | 2020 |